89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-4099-8
Abstract: BackgroundUp-to-date information on human epidermal growth factor receptor 2 (HER2) status in breast cancer (BC) is important, as expression can vary during the course of the disease, necessitating anti-HER2 therapy adjustments. Repeat biopsies, however, are… read more here.
Keywords: status; decision; her2 status; 89zr trastuzumab ... See more keywords
Next-generation sequencing based deep learning model for prediction of HER2 status and response to HER2-targeted neoadjuvant chemotherapy
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-025-06105-0
Abstract: For patients with breast cancer, the amplification of Human Epidermal Growth Factor 2 (HER2) is closely related to their prognosis and treatment decisions. This study aimed to further improve the accuracy and efficiency of HER2… read more here.
Keywords: deep learning; her2; learning model; model ... See more keywords
The expression of the insulin receptor in gastric cancer correlates with the HER2 status and may have putative therapeutic implications
Sign Up to like & getrecommendations! Published in 2019 at "Gastric Cancer"
DOI: 10.1007/s10120-019-00964-6
Abstract: BackgroundMetabolic reprogramming in gastric cancer (GC) involves not only an alteration of glucose metabolism, but also of insulin receptor (IR) expression. We investigated if (1) GCs express the IR in cancer cells (CC-IR) and vasculature… read more here.
Keywords: status; her2 status; gastric cancer; insulin receptor ... See more keywords
Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society
Sign Up to like & getrecommendations! Published in 2021 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-020-06017-2
Abstract: Purpose The prognosis of patients with node-negative T1b tumors according to human epidermal growth factor receptor 2 (HER2) status is not known. This group of patients has not been studied in the available randomized trials.… read more here.
Keywords: cancer; her2 status; breast cancer;
A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression
Sign Up to like & getrecommendations! Published in 2024 at "British Journal of Cancer"
DOI: 10.1038/s41416-024-02777-6
Abstract: This study aimed to investigate the distribution and changes of HER2 status in untreated tumours, in residual disease and in metastasis, and their long-term prognostic implications. This is a population-based cohort study of patients treated… read more here.
Keywords: cancer; breast cancer; neoadjuvant chemotherapy; disease ... See more keywords
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-75293-5
Abstract: The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In… read more here.
Keywords: oncology; impact her2; her2; study ... See more keywords
Cognitive function and breast cancer molecular subtype before and after chemotherapy.
Sign Up to like & getrecommendations! Published in 2023 at "Applied neuropsychology. Adult"
DOI: 10.1080/23279095.2023.2176233
Abstract: Chemotherapy-related cognitive impairment has been reported in patients with breast cancer and received growing attention due to increased survival rate. However, cognitive outcome according to pathological tumor features, especially human epidermal growth factor receptor (HER2)… read more here.
Keywords: her2 status; breast cancer; chemotherapy;
HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of clinical pathology"
DOI: 10.1093/ajcp/aqac179
Abstract: OBJECTIVES Human epidermal growth factor receptor 2 (HER2) status in endometrial cancer is usually determined by immunohistochemistry and/or in situ hybridization. We employed a novel HER2 gene protein assay (GPA) to simultaneously assesses HER2 gene… read more here.
Keywords: her2 status; her2 gene; her2; endometrial cancers ... See more keywords
Navigating the HER2 Frontier: Advancing Gastrointestinal Adenocarcinoma Diagnosis through Updated NCCN Guidelines
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Clinical Pathology"
DOI: 10.1093/ajcp/aqae129.101
Abstract: HER2-status is routinely tested in breast and upper-gastrointestinal (GI) cancers. Studies have shown the importance of anti-HER2 therapy with HER2 being a negative predictive marker in advanced colorectal cancer (CRC). Thus, recent NCCN-guidelines recommend screening… read more here.
Keywords: her2; pathology; her2 ihc; her2 status ... See more keywords
510 Transitioning to an In-House In-Situ Hybridisation Assay Accelerates Indeterminate HER-2 Lesion Results
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Surgery"
DOI: 10.1093/bjs/znab259.209
Abstract: NICE guidelines 1.6.5 recommend that: ‘HER2 status [should be] available and recorded at the pre-operative multidisciplinary team (MDT) meeting when systemic treatment is discussed,’ to aid decision-making regarding neoadjuvant therapy. However, indeterminate HER2 lesions require… read more here.
Keywords: situ hybridisation; her2 status; time; decision making ... See more keywords
PO-506 The dynamics of HER2 status in esophageal adenocarcinoma
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-eacr25.1007
Abstract: Introduction Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined… read more here.
Keywords: status; discordance; her2 status; treatment ... See more keywords